Form 4: Bausch + Lomb Director Steven Collis Receives RSU Grant

Director Steven H. Collis acquired 15,842 common shares of Bausch + Lomb Corporation via an annual restricted share unit grant.

Summary

• Director Steven H. Collis was granted 15,842 restricted share units (RSUs) on May 26, 2026.
• The grant was issued under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• Following this transaction, the director's total beneficial ownership increased to 42,003 common shares.
• The RSUs are scheduled to vest on the date immediately preceding the next annual meeting of shareholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial strategy.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Standard annual incentive grant indicates normal corporate governance practices.

Negatives

• None identified.

Risks

• Market price volatility of Bausch + Lomb common shares could impact the ultimate value of the RSU grant.

Future Outlook

The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are a standard practice in the pharmaceutical and medical device industry to ensure long-term alignment with shareholder interests.

Comparison to Industry Standards

• The grant structure is consistent with standard corporate governance practices for large-cap healthcare companies.
• The use of an Omnibus Incentive Plan is typical for publicly traded entities of this size.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard annual compensation event.

Next Steps

• Vesting of the RSUs prior to the next annual meeting of shareholders.

Key Dates

Keywords

Bausch + Lomb, BLCO, Director Compensation, Insider Trading, Form 4, Equity Grant